Download our Catalog and Resource Notes
Customer Service or Scientific Support
What if I knew how well delivery of CRISPR/Cas9 ribonucleoproteins works?
Learn more about how delivery of CRISPR plasmids compares with delivery of ribonucleoproteins (RNPs) from our most recent white paper, Efficient CRISPR/Cas9 Delivery Using Nucleofector™ Technology: Comparison of Plasmid- and RNP-based Editing.
The authors developed a Nucleofection-based protocol for comparing NHEJ and HDR frequencies resulting from CRISPR/Cas9 delivered as plasmid or RNPs in K562 and Neuro2A cells.
Register to download the white paper from our technical resource collection.
Find out more about Nucleofector™ Technology and genome editing.
Solving Today's Challenges in Immunotherapy
Lonza can provide high quality primary cells,
transfection technology and services to support your transition from research into therapy.
Learn more about other immunotherapy products and resources:
Register to download PDFs >
White Papers and Technical Guides
Register and download these White Papers and Technical Guides on immunotherapy:
Download PDF >
Request Printed Copy >
Free poster: Therapeutic approaches to enhance natural killer cell cytotoxicity
published by Nature Reviews Drug Discovery
Natural killer (NK) cells are emerging as attractive candidates for new immunotherapeutic approaches – they have the potential to induce powerful antigen-independent immune responses against malignancies. Lonza has sponsored a poster, published by Nature Reviews Drug Discovery, which discusses NK cells in immunotherapy.
Download the free poster as a high-resolution PDF, and request your own printed copy to display in your lab.
View Recording >
Webinar: Cancer Immunotherapy
presented by Nature
has the potential to achieve long-lasting regression and prevent relapse in
cancer patients. View a recording of the Nature webinar, sponsored by Lonza to hear panel experts describe some of the most promising approaches to cancer immunotherapy, and the challenges that remain in translating scientific advances to clinical use.